Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 7/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | EDNRB | P24530 | 1/20 | 0.43 |
| ▸ | EDNRA | P25101 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4892790 | 0.88 | HDAC1 (0.50) | CYP3A4HDAC1HDAC6PTGS1PTGS2 | |
| SCHEMBL6652167 | 0.83 | MCHR1 (0.48) | CYP3A4HDAC1HDAC6MCHR1MAPKAPK2 | |
| Hydrochloric Acid SCHEMBL7131399 | 0.83 | HDAC1 (0.54) | HDAC1HDAC6PTGS1PTGS2 | |
| SCHEMBL8035118 | 0.81 | CYP3A4 (0.58) | CYP3A4HDAC1HDAC6HTR6 | |
| SCHEMBL8025072 | 0.81 | HDAC1 (0.69) | HDAC1HDAC6HTR6 | |
| SCHEMBL6650620 | 0.79 | HDAC1 (0.46) | CYP3A4HDAC1HDAC6MCHR1HTR6 | |
| SCHEMBL13141908 | 0.79 | HDAC1 (0.64) | HDAC1HDAC6PTGS1PTGS2 | |
| SCHEMBL13142351 | 0.77 | HTR6 (0.69) | CYP3A4PTGS1PTGS2HTR6 | |
| SCHEMBL28074607 | 0.77 | EGFR (0.50) | HDAC6PTGS1MAPKAPK2EDNRBEDNRA | |
| SCHEMBL4127644 | 0.75 | HDAC1 (0.56) | HDAC1HDAC6PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1015451-B1 | TETRAHYDRO GAMMA-CARBOLINES | JANSSEN PHARMACEUTICA NV (BE) | 2003-06-18 | — | — | EP | disclosed |
| US-6506768-B2 | Serotonergic modulators; for treatment of disorders of the central nervous system including psychotic disorders, hypertension and vascular disorders, migraine | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-01-14 | — | — | US | disclosed |
| US-20020103209-A1 | Tetrahydro gamma-carbolines | KENNIS LUDO EDMOND JOSEPHINE (BE) | 2002-08-01 | — | — | US | disclosed |
| US-6303614-B1 | FOR THERAPY PSYCHOTIC DISORDER SELECTED FROM DEPRESSION, ANXIETY OR PSYCHOSIS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-10-16 | — | — | US | disclosed |
| EP-1015451-A1 | TETRAHYDRO GAMMA-CARBOLINES | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-07-05 | — | — | EP | disclosed |
| EP-0905136-A1 | Tetrahydro gamma-carbolines | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-03-31 | — | — | EP | disclosed |
| WO-1999012926-A1 | TETRAHYDRO GAMMA-CARBOLINES | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103209-A1 | Tetrahydro gamma-carbolines | OPRD1, CYP1B1, CBR1 | CYP3A4 42/4885HDAC1 1480/4885HDAC6 1853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.